370 related articles for article (PubMed ID: 30224377)
1. Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers.
Elion DL; Jacobson ME; Hicks DJ; Rahman B; Sanchez V; Gonzales-Ericsson PI; Fedorova O; Pyle AM; Wilson JT; Cook RS
Cancer Res; 2018 Nov; 78(21):6183-6195. PubMed ID: 30224377
[TBL] [Abstract][Full Text] [Related]
2. Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment.
Elion DL; Cook RS
Oncotarget; 2018 Jun; 9(48):29007-29017. PubMed ID: 29989043
[TBL] [Abstract][Full Text] [Related]
3. Delivery of 5'-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy.
Jacobson ME; Wang-Bishop L; Becker KW; Wilson JT
Biomater Sci; 2019 Jan; 7(2):547-559. PubMed ID: 30379158
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma.
Li Y; Song Y; Li P; Li M; Wang H; Xu T; Yu X; Yu Y; Tai Y; Chen P; Cai X; Wang X; Xiang L; Deng R; Zhang X; Gao L; Wang X; Liu J; Cao F
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152220
[TBL] [Abstract][Full Text] [Related]
5. RIG-I-Mediated STING Upregulation Restricts Herpes Simplex Virus 1 Infection.
Liu Y; Goulet ML; Sze A; Hadj SB; Belgnaoui SM; Lababidi RR; Zheng C; Fritz JH; Olagnier D; Lin R
J Virol; 2016 Oct; 90(20):9406-19. PubMed ID: 27512060
[TBL] [Abstract][Full Text] [Related]
6. An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation.
Castiello L; Zevini A; Vulpis E; Muscolini M; Ferrari M; Palermo E; Peruzzi G; Krapp C; Jakobsen M; Olagnier D; Zingoni A; Santoni A; Hiscott J
Cancer Immunol Immunother; 2019 Sep; 68(9):1479-1492. PubMed ID: 31463653
[TBL] [Abstract][Full Text] [Related]
7. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.
Duewell P; Steger A; Lohr H; Bourhis H; Hoelz H; Kirchleitner SV; Stieg MR; Grassmann S; Kobold S; Siveke JT; Endres S; Schnurr M
Cell Death Differ; 2014 Dec; 21(12):1825-37. PubMed ID: 25012502
[TBL] [Abstract][Full Text] [Related]
8. The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicity.
Girone C; Calati F; Lo Cigno I; Salvi V; Tassinari V; Schioppa T; Borgogna C; Lospinoso Severini L; Hiscott J; Cerboni C; Soriani A; Bosisio D; Gariglio M
Cancer Immunol Immunother; 2023 Sep; 72(9):3097-3110. PubMed ID: 37356050
[TBL] [Abstract][Full Text] [Related]
9. Nasopharyngeal carcinoma progression is mediated by EBER-triggered inflammation via the RIG-I pathway.
Duan Y; Li Z; Cheng S; Chen Y; Zhang L; He J; Liao Q; Yang L; Gong Z; Sun LQ
Cancer Lett; 2015 May; 361(1):67-74. PubMed ID: 25721089
[TBL] [Abstract][Full Text] [Related]
10. Advancing Immunotherapy in Metastatic Breast Cancer.
Mansour M; Teo ZL; Luen SJ; Loi S
Curr Treat Options Oncol; 2017 Jun; 18(6):35. PubMed ID: 28534250
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy.
Wang-Bishop L; Wehbe M; Pastora LE; Yang J; Kimmel BR; Garland KM; Becker KW; Carson CS; Roth EW; Gibson-Corley KN; Ulkoski D; Krishnamurthy V; Fedorova O; Richmond A; Pyle AM; Wilson JT
ACS Nano; 2024 May; 18(18):11631-11643. PubMed ID: 38652829
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer.
Das M; Shen L; Liu Q; Goodwin TJ; Huang L
Mol Ther; 2019 Mar; 27(3):507-517. PubMed ID: 30545600
[TBL] [Abstract][Full Text] [Related]
13. Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells.
Zhong M; Zhong C; Cui W; Wang G; Zheng G; Li L; Zhang J; Ren R; Gao H; Wang T; Li X; Che J; Gohda E
BMC Cancer; 2019 May; 19(1):439. PubMed ID: 31088527
[TBL] [Abstract][Full Text] [Related]
14. The anticancer functions of RIG-I-like receptors, RIG-I and MDA5, and their applications in cancer therapy.
Wu Y; Wu X; Wu L; Wang X; Liu Z
Transl Res; 2017 Dec; 190():51-60. PubMed ID: 28917654
[TBL] [Abstract][Full Text] [Related]
15. BRD4 Couples NF-κB/RelA with Airway Inflammation and the IRF-RIG-I Amplification Loop in Respiratory Syncytial Virus Infection.
Tian B; Yang J; Zhao Y; Ivanciuc T; Sun H; Garofalo RP; Brasier AR
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077651
[TBL] [Abstract][Full Text] [Related]
16. RIG-I activation is critical for responsiveness to checkpoint blockade.
Heidegger S; Wintges A; Stritzke F; Bek S; Steiger K; Koenig PA; Göttert S; Engleitner T; Öllinger R; Nedelko T; Fischer JC; Makarov V; Winter C; Rad R; van den Brink MRM; Ruland J; Bassermann F; Chan TA; Haas T; Poeck H
Sci Immunol; 2019 Sep; 4(39):. PubMed ID: 31519811
[TBL] [Abstract][Full Text] [Related]
17. RIG-I Promotes Cell Viability, Colony Formation, and Glucose Metabolism and Inhibits Cell Apoptosis in Colorectal Cancer by NF-
Liu Y; Ye S; Zhu Y; Chen L; Zhang Z
Dis Markers; 2022; 2022():1247007. PubMed ID: 35242239
[TBL] [Abstract][Full Text] [Related]
18. Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity.
Thier B; Zhao F; Stupia S; Brüggemann A; Koch J; Schulze N; Horn S; Coch C; Hartmann G; Sucker A; Schadendorf D; Paschen A
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35697379
[TBL] [Abstract][Full Text] [Related]
19. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I.
Brägelmann J; Lorenz C; Borchmann S; Nishii K; Wegner J; Meder L; Ostendorp J; Ast DF; Heimsoeth A; Nakasuka T; Hirabae A; Okawa S; Dammert MA; Plenker D; Klein S; Lohneis P; Gu J; Godfrey LK; Forster J; Trajkovic-Arsic M; Zillinger T; Haarmann M; Quaas A; Lennartz S; Schmiel M; D'Rozario J; Thomas ES; Li H; Schmitt CA; George J; Thomas RK; von Karstedt S; Hartmann G; Büttner R; Ullrich RT; Siveke JT; Ohashi K; Schlee M; Sos ML
Nat Commun; 2021 Sep; 12(1):5505. PubMed ID: 34535668
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 3 and RIG-I-like receptor activation induces innate antiviral responses in mouse ovarian granulosa cells.
Yan K; Zhu W; Yu L; Li N; Zhang X; Liu P; Chen Q; Chen Y; Han D
Mol Cell Endocrinol; 2013 Jun; 372(1-2):73-85. PubMed ID: 23567548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
